

# Vincent C Tam

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1788163/publications.pdf>

Version: 2024-02-01

19  
papers

1,244  
citations

1163117  
8  
h-index

940533  
16  
g-index

20  
all docs

20  
docs citations

20  
times ranked

1245  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. , 2022, 1, .		298
2	Dosing, efficacy and safety of lenvatinb in the real-world treatment of hepatocellular carcinoma: Results from a Canadian database. Liver Cancer International, 2022, 3, 119-127.	1.3	1
3	Optimizing Survival and the Changing Landscape of Targeted Therapy for Intermediate and Advanced Hepatocellular Carcinoma: A Systematic Review. Journal of the National Cancer Institute, 2021, 113, 123-136.	6.3	28
4	Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study.. Journal of Clinical Oncology, 2021, 39, 289-289.	1.6	6
5	Metastatic pancreatic cancer with complete response to FOLFIRINOX treatment. BMJ Case Reports, 2021, 14, e238395.	0.5	3
6	Oncology education for family medicine residents: a national needs assessment survey. BMC Medical Education, 2020, 20, 283.	2.4	10
7	Effect of sorafenib starting dose and dose intensity on survival in patients with hepatocellular carcinoma: Results from a Canadian Multicenter Database. Cancer Medicine, 2020, 9, 4918-4928.	2.8	7
8	Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma. Clinical Cancer Research, 2020, 26, 4795-4804.	7.0	58
9	Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma. JAMA Oncology, 2019, 5, 1582.	7.1	91
10	Cytotoxic Curli Intermediates Form during Salmonella Biofilm Development. Journal of Bacteriology, 2019, 201, .	2.2	12
11	Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014. Cancer, 2017, 123, 4672-4679.	4.1	16
12	Tumour thrombus of the inferior vena cava extending into the right atrium in the setting of colon cancer. BMJ Case Reports, 2017, 2017, bcr2016218107.	0.5	4
13	The effect of sorafenib (S) starting dose and dose intensity on survival in patients with advanced hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2017, 35, 400-400.	1.6	2
14	A population-based study of biliary tract cancers (BTCs) in Alberta, Canada: How do our patients fare?. Journal of Clinical Oncology, 2017, 35, 246-246.	1.6	0
15	Application of the ASCO framework for assessing value in metastatic colorectal cancer clinical trials.. Journal of Clinical Oncology, 2017, 35, 687-687.	1.6	0
16	Developing Canadian oncology education goals and objectives for medical students: a national modified Delphi study. CMAJ Open, 2016, 4, E359-E364.	2.4	7
17	Compendium of Unpublished Phase III Trials in Oncology: Characteristics and Impact on Clinical Practice. Journal of Clinical Oncology, 2011, 29, 3133-3139.	1.6	34
18	Consistency of Phase III Clinical Trial Abstracts Presented at an Annual Meeting of the American Society of Clinical Oncology Compared With Their Subsequent Full-Text Publications. Journal of Clinical Oncology, 2008, 26, 2205-2211.	1.6	29

#	ARTICLE	IF	CITATIONS
19	Frequency, type and clinical importance of medication history errors at admission to hospital: a systematic review. Cmaj, 2005, 173, 510-515.	2.0	638